Recombinant Human CHN2 protein

**Background of CHN2 Recombinant Protein**

CHN2 (Chimerin 2), encoded by the *CHN2* gene, is a member of the chimerin family of GTPase-activating proteins (GAPs) that regulate Rho GTPases, key signaling molecules involved in cytoskeletal dynamics, cell motility, and neuronal development. CHN2 specifically targets Rac and Cdc42 GTPases, promoting their transition from active GTP-bound to inactive GDP-bound states, thereby modulating downstream cellular processes such as axon guidance, synaptic plasticity, and dendritic morphogenesis.

The recombinant CHN2 protein is engineered through molecular cloning techniques, typically expressed in *E. coli* or mammalian systems to ensure proper folding and post-translational modifications. Its recombinant form enables researchers to study CHN2's biochemical properties, interactions, and regulatory mechanisms in controlled experimental settings. Dysregulation of CHN2 has been implicated in neurological disorders (e.g., schizophrenia, Alzheimer’s disease) and cancer, where aberrant Rho signaling contributes to tumor invasion and metastasis.

Current research focuses on characterizing CHN2's role in signal transduction pathways and its potential as a therapeutic target. Recombinant CHN2 is also utilized in drug screening assays to identify compounds that modulate its GAP activity or restore dysregulated pathways. Despite progress, challenges remain in understanding tissue-specific functions and isoform diversity (CHN2 has multiple splice variants). Advances in structural biology and CRISPR-based models are expected to deepen insights into CHN2's physiological and pathological relevance, paving the way for translational applications in neurology and oncology.